Healthcare Industry News: PASCAL Photocoagulator
News Release - January 8, 2009
Optimedica Taps Stephen P. Hanlon As New Vice President Of Research And DevelopmentSANTA CLARA, Calif., January 8, 2009 - (HSMN NewsFeed) - Global ophthalmic company OptiMedica Corp. has appointed medical device industry veteran Stephen P. Hanlon as vice president of research and development. In this newly created position, Hanlon will be responsible for driving new technology and product innovation for the company.
“Steve’s deep medical technology experience and proven track record of innovation make him the perfect choice to lead OptiMedica’s substantial research and development efforts as we develop new additions to our growing portfolio of products,” said Mark J. Forchette, president and chief executive officer. “He is joining a very seasoned management team that has demonstrated remarkable success designing, developing and commercializing PASCAL technology that has already benefited hundreds of thousands of patients around the world. We look forward to working with Steve to accelerate the development of new technologies and products that meet the highest standards of excellence in the ophthalmic industry.”
Hanlon brings to OptiMedica more than 25 years of leadership experience in medical technology research and development, with areas of focus including stereotactic radiosurgery, image-guided surgery, implantable devices, electrosurgery and dialysis products. He was previously vice president of research and development for Boston Scientific’s Neurovascular Division, where he oversaw a 100-person multi-disciplinary department and numerous successful product launches. Prior to Boston Scientific, he served as vice president of operations for Photoelectron Corp. as well as vice president and general manager of the Radionics division of Tyco Healthcare (now Covidien).
“OptiMedica represents the exciting convergence of sophisticated technology with a clear need for better treatment options for a large and growing patient population,” said Hanlon. “I look forward to bringing my experience with best-in-class medical device companies to bear for OptiMedica in this fast-moving, high-tech market.”
Based in Santa Clara, Calif., OptiMedica Corp. is a global ophthalmic company dedicated to advancing the practice of ophthalmology for the benefit of physicians and their patients. The company holds the exclusive license to the PASCAL Photocoagulator technology, which was originally developed at Stanford University. OptiMedica is funded by Kleiner Perkins Caufield & Byers, Alloy Ventures and DAG Ventures. For more information, please visit www.optimedica.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.